De-risking antibody discovery through comprehensive developability profiling
Select leads with confidence by integrating biophysical assays, computational analysis, and clinical benchmarking from the earliest stages of discovery.
Despite strong target binding, many therapeutic antibodies fail late in development due to preventable issues related to stability, manufacturability, or pharmacokinetics. Alloy’s integrated developability platform addresses these risks early by embedding comprehensive profiling directly into antibody discovery and optimization workflows, including:
A broad suite of orthogonal biophysical assays assessing stability, solubility, self-interaction, polyreactivity, hydrophobicity, and non-specific binding
AI/ML-driven computational models trained on historical assay data and clinical benchmarks to triage large sequence pools efficiently
High-throughput antibody production and QC in native and complex formats to ensure data reflects true therapeutic behavior
Benchmarking against clinical-stage antibodies to contextualize risk and support data-driven decision-making
Complete this form to download the white paper
Overcome late-stage risk in antibody development
Comprehensive developability assessment is a critical determinant of clinical success, enabling teams to identify liabilities early, prioritize robust candidates, and accelerate progression into development.
Discover how Alloy’s developability platform enables:
Early identification of biophysical liabilities that impact stability, aggregation, viscosity, and clearance
Integration of in vitro and in silico insights to guide smarter lead selection and engineering decisions
Confident comparison of candidates through benchmarking against approved and clinical-stage antibodies
Rapid iteration during lead optimization using high-throughput expression, QC, and re-screening workflows
Reduced downstream risk by advancing antibodies that balance biological activity with manufacturability and safety
